Elafibranor治疗原发性胆汁性胆管炎的两年安慰剂对照及长期开放标签数据:ELATIVE® III期试验
ELATIVE® III期试验显示,elafibranor 80mg治疗原发性胆汁性胆管炎患者104周时生化应答率64.3%、ALP正常化率10.7%,安慰剂组均为0%;开放标签延伸至3年,生化改善持续,疲劳和瘙痒有数值改善,安全性良好。
要点
- Elafibranor 80mg在104周时生化应答率64.3%,ALP正常化率10.7%,安慰剂组均为0%。
- 开放标签延伸至156周,持续elafibranor组生化应答率58.8%-65.0%,ALP正常化率15.0%-25.0%。
- 基线中重度疲劳或瘙痒患者,elafibranor组PFSF 7a和PBC WI NRS评分有数值改善。
核心结论
- Elafibranor治疗原发性胆汁性胆管炎患者,2年双盲期内生化应答和ALP正常化显著优于安慰剂。
- 开放标签延伸至3年,生化改善持续,疲劳和瘙痒有数值改善,安全性良好。
研究设计与样本
- ELATIVE® III期试验(NCT04526665),161例患者随机2:1接受elafibranor 80mg或安慰剂。
- 双盲期包括52周共同期(Part 1)和可变期(Part 2),最长104周;完成Part 1者可进入开放标签延伸接受elafibranor。
主要发现
- 双盲期Part 2第104周,elafibranor组生化应答率64.3%(18/28),ALP正常化率10.7%(3/28),安慰剂组均为0%。
- 基线中重度疲劳或瘙痒患者,第104周PFSF 7a评分平均变化elafibranor组-6.3(SE 2.2)vs安慰剂组-0.4(SE 1.2)。
- 基线中重度瘙痒患者,第104周PBC WI NRS评分平均变化elafibranor组-4.1(SE 1.0)vs安慰剂组0.3(SE 1.2)。
- 开放标签延伸中,持续elafibranor组第104周和156周生化应答率分别为58.8%(47/80)和65.0%(13/20),ALP正常化率分别为15.0%(12/80)和25.0%(5/20)。
- 交叉至elafibranor组治疗52周后,生化应答率51.2%(21/41),ALP正常化率22.0%(9/41)。
关键数值与推荐
- 双盲期第104周生化应答率:elafibranor组64.3% vs 安慰剂组0%。
- 双盲期第104周ALP正常化率:elafibranor组10.7% vs 安慰剂组0%。
- 持续elafibranor组第156周生化应答率65.0%,ALP正常化率25.0%。
临床怎么用
- Elafibranor可作为PBC患者对一线治疗应答不足或不耐受时的长期治疗选择。
- 治疗期间需监测生化应答和ALP正常化情况,并关注疲劳和瘙痒症状变化。
局限性
- 开放标签延伸数据非对照,长期疗效和安全性需进一步验证。
- 疲劳和瘙痒的改善为数值改善,未报告统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We report 104-week placebo-controlled data and long-term open-label extension (OLE) data from the ongoing ELATIVE® phase III trial (NCT04526665) of elafibranor in primary biliary cholangitis (PBC). METHODS: A total of 161 patients were randomized 2:1 to elafibranor 80 mg or placebo. The double-blind period (DBP) consisted of 52-week common (Part 1) and variable (Part 2) periods. Patients completing Part 1 continued into Part 2 until all patients completed Part 1, or for a maximum of 104 weeks. All patients completing Part 1 could enter the OLE and receive elafibranor. RESULTS: At Week 104 in DBP Part 2, 64.3% (18/28) and 10.7% (3/28) of elafibranor-treated patients achieved biochemical response and alkaline phosphatase (ALP) normalization, respectively, vs. no placebo-treated patients. In patients with moderate-to-severe fatigue or pruritus at baseline, mean (SE) changes to Week 104 in PROMIS Fatigue Short Form 7a (PFSF 7a) and PBC Worst-Itch Numeric Rating Scale (PBC WI NRS) were -6.3 (2.2) vs. -0.4 (1.2) and -4.1 (1.0) vs. 0.3 (1.2), respectively, with elafibranor vs. placebo. A total of 138 patients entered the OLE (continuous elafibranor: n = 93; crossover elafibranor: n = 45). Among patients continuing elafibranor, 58.8% (47/80) and 65.0% (13/20) achieved biochemical response, and 15.0% (12/80) and 25.0% (5/20) achieved ALP normalization at Weeks 104 and 156, respectively. In crossover patients, 51.2% (21/41) and 22.0% (9/41) achieved biochemical response and ALP normalization after 52 weeks, respectively. In patients continuing elafibranor with moderate-to-severe symptoms at baseline, mean (SE) changes to Week 130 in PFSF 7a and PBC WI NRS were -4.8 (1.5) and -4.0 (0.7), respectively. There were no unexpected safety findings. CONCLUSIONS: Through 3 years of treatment, elafibranor led to sustained biochemical improvements and was generally well tolerated, with numerical improvements in fatigue and pruritus. IMPACT AND IMPLICATIONS: Given the chronic, progressive nature of primary biliary cholangitis (PBC), the long-term efficacy and tolerability of treatments is important. Here, we present 2-year results from the double-blind period, and long-term data from the ongoing open-label extension of the phase III ELATIVE® trial, wherein elafibranor (a peroxisome proliferator-activated receptor-α/δ agonist) treatment led to sustained biochemical improvements, stable non-invasive tests of fibrosis, and numerical improvements in fatigue and pruritus, through 3 years. Elafibranor demonstrated a favorable safety profile up to a maximum treatment exposure of 3.5 years, including in patients crossing over from placebo. These findings support elafibranor as a durable long-term treatment for patients with PBC, and are particularly relevant for clinicians managing patients with inadequate response or intolerance to first-line treatments. TRIAL REGISTRATION: NCT04526665 (https://clinicaltrials.gov/study/NCT04526665); first registered 08/26/2020.
引用
- Kowdley KV, Bowlus CL, Levy C, et al. Elafibranor in primary biliary cholangitis: Two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial. J Hepatol. 2026. PMID: 42660235. doi:10.1016/j.jhep.2026.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。